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There are a variety of treatment options for patients with spinal metastasis,  and predicting prognosis 
is essential for selecting the proper treatment.  The purpose of the present study was to identify the 
signiﬁcant prognostic factors for the survival of patients with spinal metastasis.  We retrospectively 
reviewed 143 patients with spinal metastasis.  The median age was 61 years.  Eleven factors reported 
previously were analyzed using the Cox proportional hazards model: gender,  age,  performance status,  
neurological deﬁcits,  pain,  type of primary tumor,  metastasis to major organs,  previous chemother-
apy,  disease-free interval before spinal metastasis,  multiple spinal metastases,  and extra-spinal bone 
metastasis.  The average survival of study patients after the ﬁrst visit to our clinic was 22 months.  
Multivariate survival analysis demonstrated that type of primary tumor (hazard ratio [HR]＝6.80,  p
＜0.001),  metastasis to major organs (HR＝2.01,  p＝0.005),  disease-free interval before spinal metasta-
sis (HR＝1.77,  p＝0.028),  and extra-spinal bone metastasis (HR＝1.75,  p＝0.017) were signiﬁcant 
prognostic factors.  Type of primary tumor was the most powerful prognostic factor.  Other prognos-
tic factors may diﬀer among the types of primary tumor and may also be closely associated with pri-
mary disease activity.  Further analysis of factors predicting prognosis should be conducted with 
respect to each type of primary tumor to help accurately predict prognosis.
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pinal metastasis occurs in 30-60ｵ of patients 
with cancer [1-3],  and can result in poor prog-
nosis [4].  There are a variety of options for the 
treatment of spinal metastasis.  Some patients are 
treated non-surgically by radiotherapy or chemother-
apy [5],  while others undergo surgical treatments 
such as posterior decompression with or without 
instrumentation [6,  7].  Recently,  the more radical 
operation of total en-bloc spondylectomy has been 
applied,  with the aim of complete local control of 
spinal metastasis [8].  It is diﬃcult to select the 
proper treatment option for patients with spinal 
metastasis,  and predicting survival is the key factor in 
the selection of the best option.  Many studies have 
been conducted on the biological characteristics of 
cancers or the treatment modalities that might aﬀect 
the prognosis of patients with metastasis [4,  5,  
9-11].  Various scoring systems for spinal metastasis 
have also been proposed for predicting survival and 
selecting the ideal treatment modality [6,  7,  12,  
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13].  Although these scoring systems can be useful in 
predicting prognosis and deciding on proper treatment,  
there have been few reports using multivariate sur-
vival analysis to assess the signiﬁcant prognostic fac-
tors for patients with spinal metastasis.
　 In this study,  we analyzed the clinical features of 
patients with spinal metastasis who were referred to 
our clinic,  and determined signiﬁcant prognostic fac-
tors for survival using the Cox proportional hazards 
model.
Patients and Methods
　 We analyzed 143 patients with spinal metastasis 
originating from various cancers and sarcomas who 
were referred to the Department of Orthopaedic 
Surgery of Okayama University Hospital and Okayama 
Medical Center between January 1990 and December 
2008.  Detailed information regarding each patientʼs 
characteristics and clinical signs and symptoms were 
entered on an initial evaluation form.  There were 91 
males and 52 females.  The median age was 61 years 
(range,  4 to 83 years).  The mean follow-up period 
was 21 months (range,  1 to 127 months).  The types of 
primary tumor for the 143 patients,  including of 33 
lung cancers,  18 prostate cancers,  14 breast cancers,  
and other types of cancer,  are presented in Table 1.  
Lung,  prostate,  and breast cancers accounted for 
46ｵ of the total number of primary tumors in all 
patients.
　 To localize spinal metastasis,  imaging such as 
radiography,  computed tomography (CT),  and/or 
magnetic resonance imaging (MRI) was performed ﬁrst 
on the symptomatic spinal level related to back pain 
and/or spinal cord injury.  Patients with spinal metas-
tasis then underwent systemic imaging assessment 
using bone scintigraphy,  MRI on the entire spinal 
column,  and/or whole-body CT.
　 The treatment strategy for the spinal metastasis 
was thoroughly discussed with the medical oncologists 
who took primary care of the patients,  especially 
focusing on the patientsʼ general condition and progno-
sis.  Surgery was considered mainly based on the 
severity of intractable pain,  neurological status,  and/
or spinal instability (Table 2).  Seventy-two surgeries 
were performed,  including 55 laminectomies and pos-
terior stabilizations,  10 combined anterior and poste-
rior fusions,  4 total en-bloc spondylectomies,  and 3 
anterior fusions only.  Total en-bloc spondylectomies 
were performed for 2 patients with thyroid cancer,  1 
with renal cancer,  and 1 with prostate cancer.
　 Eleven prognostic factors were investigated (Table 
3).  Each factor was grouped in up to 3 categories for 
statistical analysis.  Age was categorized into groups 
of younger than 60 years and 60 years or older [13].  
Performance status (PS),  assessed by the Eastern 
Cooperative Oncology Group (ECOG) PS scale [14],  
was categorized into 2 groups of PS 0 to 2 and 3 to 4.  
Neurological deﬁcit was assessed using the Frankel 
classiﬁcation of spinal cord injury; grade A: complete 
neurological injury,  B: preserved sensation only,  
C : preserved motor non-functional,  D :  
preserved motor function,  E: normal motor [15].  
Neurological deﬁcit was divided into 2 categories,  
Frankel grades A to C and D to E.  Type of primary 
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Table 1　 The primary tumors in the 143 patients
Primary lesion Number of patients
Lung cancer 33
Prostate cancer 18
Breast cancer 14
Endometrial,  cervical,  ovarian,  and uterine 
cancer 12
Renal cell cancer 10
Thyroid cancer 8
Bladder cancer 6
Colon and rectal cancer 6
Hepatocellular cancer 5
Stomach cancer 5
Bone and soft tissue sarcoma 4
Others 19
Unknown origin 3
Total 143
Table 2　 Treatment
Treatment n
Surgery＋Chemotherapy＋Radiotherapy 18
Surgery＋Radiotherapy 20
Surgery＋Chemotherapy 16
Surgery 18
Chemotherapy＋Radiotherapy 38
Chemotherapy 19
Radiotherapy 8
Palliative 6
Total 143
tumor was divided into 3 groups according to growth 
rate of the primary disease of the Tomita classiﬁca-
tion: breast,  prostate,  and thyroid cancer as slow 
growth,  other cancer and sarcoma as moderate 
growth,  and lung,  bladder,  liver,  colon,  and stomach 
cancer as rapid growth [7].  Previous chemotherapy 
for primary cancer was classiﬁed as a primary-site 
related factor [13].  Disease-free interval before spi-
nal metastasis was divided into 2 categories,  less than 
12 months and 12 months or more,  and was classiﬁed 
as a skeletal metastasis-related factor [13].
　 A Kaplan-Meier actuarial survival curve was cre-
ated using the ﬁrst visit date as the starting point of 
follow-up.  Univariate analysis was performed using a 
log-rank test [16].  The Cox proportional hazards 
model was used for the multivariate analysis.  Evalua-
tion of the eﬀect of multiple variables on the survival 
of patients was carried out using a stepwise propor-
tional hazard analysis.  In all analyses,  p values of less 
than 0.05 were considered to be statistically signiﬁ-
cant.  The software program StatView version 5.0 
(SAS Institute Inc,  Cary,  NC,  USA) was used for all 
analyses.
Results
　 At the last follow-up,  14 patients (10ｵ) were still 
alive.  The average survival of all patients was 22 
months,  ranging from 1 to 127 months.  One hundred 
and four patients complained of pain in connection with 
their spinal metastasis and required daily analgesics 
and/or narcotics.  At the ﬁrst physical examination,  
45 patients could not walk due to muscle weakness.  
According to the Frankel classiﬁcation,  4 patients 
were classiﬁed as grade A,  7 as grade B,  36 as grade 
C,  34 as grade D,  and 62 as grade E.  Twenty-three 
patients had metastasis to major organs at the time of 
diagnosis of spinal metastasis: lung (11 patients),  
liver (10),  brain (2),  and kidney (1).  One patient 
showed metastasis to both the liver and brain.
　 Thirty-seven patients (26ｵ) presented with spinal 
metastasis at the time of the primary diagnosis of 
cancer.  Forty-eight patients (34ｵ) were diagnosed 
with spinal metastasis less than 12 months after the 
primary diagnosis of cancer,  and 58 patients (40ｵ) 
were diagnosed at 12 months or longer after the pri-
mary diagnosis of cancer.  Imaging assessment revealed 
that 85 patients had multiple (2 or more) spinal metas-
tases: 2 spinal metastases in 30 patients,  3 metasta-
ses in 10 patients,  and more than 4 metastases in 45 
patients.  Multiple spinal metastases were seen in 
80ｵ of the patients with spinal metastasis of breast 
cancer,  69ｵ of the patients with prostate cancer,  
and 67ｵ of the patients with bladder cancer.  Thirty-
one patients had bone metastasis not only to the spine 
but also to other bones in the extremities or trunk.
　 Univariate survival analysis demonstrated that type 
of primary tumor (Fig.  1A),  metastasis to major 
organs (Fig.  1B),  disease-free interval before spinal 
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Table 3　 Distribution of potentially prognostic factors in the 143 
patients
n
Patient-related factor
　Gender
Male 91
Female 52
　Age (yrs)
＜60 89
≧60 54
　Performance status
PS 0 to 2 99
PS 3 to 4 44
　Neurological deﬁcits
ABC 47
DE 96
　Pain
No 39
Yes 104
Primary site-related factor
　Type of primary tumor
　　Slow: Breast,  prostate,  thyroid 39
　　Moderate: Other cancer and sarcoma 49
　　Rapid: lung,  bladder,  liver,  colon,  stomach 55
　Metastasis to major organs
No 120
Yes 23
　Previous chemotherapy
No 68
Yes 75
Skeletal metastasis-related factor
　Disease-free interval before spinal metastasis
＜12 months 85
≧12 months 58
　Multiple spinal metastasis
No 58
Yes 85
　Extra-spinal bone metastasis
No 112
Yes 31
metastasis (Fig.  1C),  and pain with spinal metastasis 
were statistically signiﬁcant prognostic factors for 
patients with spinal metastasis (Table 4).  Multivariate 
survival analysis showed that type of primary tumor 
(HR=6.80 and 1.80,  p＜0.001),  metastasis to major 
organs (HR＝2.01,  p＝0.005),  disease-free interval 
before spinal metastasis (HR＝1.77,  p＝0.028),  and 
extra-spinal bone metastasis (HR＝1.75,  p＝0.017) 
were signiﬁcant prognostic factors (Table 5).
Discussion
　 Several investigators have discussed the prognostic 
factors for patients with spinal metastasis,  and vari-
ous prognostic factors have been reported as statisti-
cally signiﬁcant for survival [5,  13,  17-26].  Stoll 
stated that the prognostic factors for a given patient 
could be discovered from the patientʼs disease history 
and clinical ﬁndings [4].  Several scoring assessment 
systems have been formulated for predicting survival 
and deciding on the proper treatment modality [6,  7,  
12,  13].  Although scoring systems can be useful 
clinically,  few clinicians have used multivariate analy-
sis to analyze the statistical independence of each 
prognostic factor.  We studied 11 factors used as 
components of the Tokuhashi score,  the Tomita score,  
and the Katagiri score,  and analyzed them using the 
Cox proportional hazards model.  Our multivariate 
analysis of all the patients with spinal metastasis 
referred to our clinic identiﬁed four variables－type 
of primary tumor,  metastasis to major organs,  dis-
ease-free interval before spinal metastasis,  and extra-
spinal bone metastasis－as signiﬁ cant prognostic fac-
tors for survival.
　 The Tokuhashi score consists of the sum of 6 
parameters.  However,  three of those－general condi-
tion as assessed by PS,  the number of metastases in 
the vertebral body,  and the Frankel grade－were not 
identiﬁed as statistically signiﬁcant prognostic factors 
in the present study.  Previous papers also demon-
strated that these were less signiﬁcant factors [5,  
25].  Van der Linden also proposed a scoring system 
for patients with spinal metastasis based on multivari-
ate analysis [27].  However,  since the scores were 
originally developed through analysis of patients with 
painful spinal metastases without neurologic impair-
ment,  assessment according to the van der Linden 
score could be limited to such patients.  The Tomita 
score and the Bauer score are similar assessment 
systems for spinal metastasis,  composed of primary 
tumor,  visceral metastasis,  and number of bone 
metastases,  since pathological fracture,  as one of 
Bauerʼs variables,  was evident only in the patients 
with metastasis in the extremities [7,  12].  Multi-
variate analysis in our series also showed that these 3 
prognostic factors were statistically signiﬁcant.  
Leithner et al.  evaluated the diﬀerences between the 
Tomita and Bauer scoring systems for 69 patients 
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Fig. 1　 Survival curves for prognostic factors in 143 patients with 
spinal metastasis.  A,  Type of primary tumor.  Slow growth: breast,  
prostate,  and thyroid cancer; Moderate growth: other cancer and 
sarcoma; Rapid growth: lung,  bladder,  liver,  colon,  and stomach 
cancer; B,  Survival curves for metastasis to major organs; C,  
Survival curves for disease-free interval before spinal metastasis.
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Table 4　 Univariate analysis of prognostic factors
Variables Hazard Ratio 95% CI p value
Sex
　Male
　Female 0.505 0.346-0.737 0.0004
Age
　＜60
　≧60 0.9 0.618-1.309 0.5811
Performance status
3 to 4
0 to 2 1.072 0.729-1.574 0.7247
Neurological deﬁcits
　DE
　ABC 1.056 0.727-1.534 0.7732
Pain
　No
　Yes 1.531 1.018-2.304 0.0406
Type of primary tumor
　Slow
　Moderate 1.502 0.940-2.399 ＜0.0001
　Rapid 5.013 3.083-8.150 ＜0.0001
Metastasis to major organs
　No
　Yes 2.012 1.251-3.236 0.0038
Previous chemotherapy
　No
　Yes 0.743 0.523-1.054 0.0963
Disease-free interval before spinal metastasis
　≧12 months
　＜12 months 1.815 1.259-2.614 0.0014
Multiple spinal metastasis
　No
　Yes 1.002 0.702-1.429 0.992
Extra-spinal bone metastasis
　No
　Yes 1.076 0.71-1.631 0.7296
CI,  conﬁdence interval.
Table 5　 Multivariate analysis of prognostic factors
Variables Hazard Ratio 95% CI p value
Type of primary tumor
　Slow
　Moderate 1.797 1.12-3.39 ＜0.001
　Rapid 6.802 3.62-11.5 ＜0.001
Metastases to major organs
　No
　Yes 2.01 1.09-2.95 0.0051
Disease-free interval before spinal metastasis
　ｧ12 months
　＜12 months 1.77 1.02-2.34 0.028
Extra-spinal bone metastases
　No
　Yes 1.75 1.04-2.79 0.0171
CI,  conﬁdence interval.
with spinal metastasis and showed that the Bauer 
score was a practical and highly predictive preopera-
tive scoring system [25].  The Bauer score was based 
on multivariate analysis for several prognostic values 
and could be suitable for predicting prognosis.
　 Some authors have reported that metastasis to 
major organs was the signiﬁcant prognostic factor for 
survival of patients with spinal metastasis [5-7,  13,  
17,  21].  In particular,  Yamashita et al.  stated that 
metastasis to the major organs in patients with breast 
cancer aﬀected the prognosis,  rather than the extent 
of the spread of bone metastasis [9].  The disease-free 
interval before the occurrence of spinal metastasis was 
also reported as a prognostic factor [18,  20,  28,  
29].  In our series,  the patients with a disease-free 
interval longer than 12 months before the discovery of 
spinal metastasis were the patients who mainly had 
primary tumors with slow growth,  such as thyroid and 
breast cancer.  The disease-free interval before the 
occurrence of spinal metastasis might reﬂect the activ-
ity of the primary disease,  indicating that a long 
interval could be a sign of low activity of the disease,  
thereby portending a probable long survival after 
spinal metastasis [18].
　 Extra-spinal bone metastasis seemed to be a less 
signiﬁcant prognostic factor [9,  13,  23,  25].  
Katagiri et al.  studied the locations of skeletal metas-
tasis for patients with bone metastasis and found that 
the grouping of the skeletal metastases according to 
site was not signiﬁcantly associated with survival 
[13].  However,  in patients with breast cancer,  
Yamashita et al.  showed that widespread distribution 
of bone metastasis was the prognostic factor [9].  
Rigaud et al.  also demonstrated that patients with axial 
metastasis had a better prognosis than that of patients 
with appendicular metastasis in cases of prostate 
cancer [24].  Our univariate analysis identiﬁed extra-
spinal bone metastasis as a less signiﬁcant prognostic 
factor for survival.  However,  our multivariate analy-
sis demonstrated that extra-spinal bone metastasis was 
one of the signiﬁcant prognostic factors.  The reason 
might be that the type of primary tumor could be a 
very strong prognostic factor and univariate analysis 
might be unable to identify its signiﬁcance.
　 Tokuhashi et al.  reported that the average survival 
rates for patients with spinal metastasis of stomach 
and lung cancer were statistically shorter than the 
survival rates of patients with thyroid,  prostate,  
breast,  and rectal cancer [6].  Many authors have also 
shown that the site of the primary tumor was the sta-
tistically signiﬁcant factor in predicting prognosis [5,  
13,  17-26].  In the present study,  type of primary 
tumor was identiﬁed as the most powerful prognostic 
factor for patients with spinal metastasis.  Other 
prognostic factors identiﬁed in the present study can 
diﬀer among types of primary tumor and may also be 
closely associated with the activity of the primary 
disease.  Further survival analysis with regard to each 
primary tumor may lead to predicting prognosis more 
accurately for patients with spinal metastasis.
　 There were some limitations in the present study.  
Patients referred to our clinic underwent various 
previous treatments,  and the treatment strategies for 
primary cancer might have been diﬀerent among the 
referring hospitals.  Treatment of spinal metastasis 
also varied in our series; especially,  surgical treat-
ments were diﬀerent among 2 hospitals.  Treatment 
modality for spinal metastasis might aﬀect patient 
survival.  Cancers arising from a single organ,  such as 
lung cancer and breast cancer,  have diﬀerent histo-
logical subtypes as well as biological activities.  
Furthermore,  in the treatment of some types of can-
cer,  recent advances,  such as molecular-targeted 
drugs,  have dramatically changed the patientsʼ progno-
sis [30,  31].  These subtypes may have to be care-
fully considered when assessing the survival of 
patients with spinal metastasis.
　 In conclusion,  the data of the present study identi-
ﬁed the preoperative factors of type of primary tumor,  
metastasis to major organs,  disease-free interval 
before spinal metastasis,  and extra-spinal bone metas-
tasis as independent prognostic factors for survival in 
patients with spinal metastasis.  Although the type of 
primary tumor was the most signiﬁcant prognostic 
factor,  further analysis of factors predicting progno-
sis should be conducted with respect to each type of 
primary tumor.
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